Jake and TreatSMA take campaign to the Houses of Parliament

Jake Ogborne and TreatSMA visited the Houses of Parliament to meet with Jacob Rees-Mogg to highlight his and others’ need for treatment.

Jake and TreatSMA took the campaign to the Houses of Parliament on the 16th July to stress the need for access to Spinraza. Already Jake is seeing deterioration which access to Spinraza would stop. His MPs were upset that he could have walked at the time of the approval for marketing Spinraza, yet the MAA process has taken so long he does not now meet the MAA criteria. Jacob Rees-Mogg was surprised that in the original NICE announcement on the 15th May it looked like treatment should have been available but now he cannot access it. Jake’s family are desperate to access treatment for him but no matter how hard they try they are blocked

Jake Ogborne, who is 18 and comes from East Bristol, took the campaign for allowing all patients to receive Spinraza to the Houses of Parliament in order to provide MPs with real-life information on the impact of being excluded from treatment.
Jake’s grandmother’s MP Jacob Rees-Mogg has taken special interest in this case after receiving a letter from Jake’s family, the letter prompted Mr Rees-Mogg to challenge the Prime Minister on the behaviour and poor communications from NICE, asking that they should be compelled to stick with their original announcement of allowing access for all.

Jake explained that he was able to walk in 2017 as a type 3 sufferer when Spinraza received its marketing authority in Europe, however due to the protracted process for approval, and the U-turn with regards to the eligibility criteria in the MAA, he now doesn’t meet the criteria to receive treatment. Both Jake’s MP Kerry McCarthy and Jacob Rees-Mogg MP committed to do all that they can to support Jake’s ongoing fight to receive treatment, which despite many attempts by Jake’s family, is blocked at every attempt.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more